GT Biopharma (NASDAQ:GTBP) Trading 5.1% Higher – Still a Buy?

GT Biopharma, Inc. (NASDAQ:GTBP) shot up 5.1% during mid-day trading on Monday . The company traded as high as $0.3156 and last traded at $0.3086. 418,806 shares traded hands during trading, a decline of 46% from the average session volume of 780,414 shares. The stock had previously closed at $0.2935.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Wall Street Zen upgraded GT Biopharma to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GT Biopharma in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

GT Biopharma Price Performance

The stock has a market cap of $14.08 million, a price-to-earnings ratio of -0.05 and a beta of 0.90. The firm’s 50-day moving average is $0.42 and its 200 day moving average is $0.45.

GT Biopharma (NASDAQ:GTBP) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). On average, sell-side analysts forecast that GT Biopharma, Inc. will post -0.34 EPS for the current year.

Institutional Investors Weigh In On GT Biopharma

A hedge fund recently bought a new stake in GT Biopharma stock. Everhart Financial Group Inc. acquired a new position in GT Biopharma, Inc. (NASDAQ:GTBP) during the second quarter, according to its most recent 13F filing with the SEC. The firm acquired 100,000 shares of the company’s stock, valued at approximately $49,000. Everhart Financial Group Inc. owned 0.23% of GT Biopharma at the end of the most recent reporting period. 8.15% of the stock is owned by hedge funds and other institutional investors.

About GT Biopharma

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).